U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27N3O.C14H10O4
Molecular Weight 603.7068
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRENOXDIAZINE HIBENZATE

SMILES

OC(=O)C1=CC=CC=C1C(=O)C2=CC=C(O)C=C2.C(CC3=NC(CC(C4=CC=CC=C4)C5=CC=CC=C5)=NO3)N6CCCCC6

InChI

InChIKey=DISMLHKPMHZZJD-UHFFFAOYSA-N
InChI=1S/C23H27N3O.C14H10O4/c1-4-10-19(11-5-1)21(20-12-6-2-7-13-20)18-22-24-23(27-25-22)14-17-26-15-8-3-9-16-26;15-10-7-5-9(6-8-10)13(16)11-3-1-2-4-12(11)14(17)18/h1-2,4-7,10-13,21H,3,8-9,14-18H2;1-8,15H,(H,17,18)

HIDE SMILES / InChI

Description

Prenoxdiazine under the brand name Libexin is used as an antitussive agent. It was shown, that the use of this drug for pregnant women with an unproductive cough could be beneficial.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
PubMed

PubMed

TitleDatePubMed
[Study on the antitussive effect of Libexin in clinical practice].
1966 Jul 24
No teratogenic effect of prenoxdiazine: a population-based case-control study.
2007 Mar
Patents

Patents

20050002865
228
20070224187
4
20090317473
3

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
Name Type Language
PRENOXDIAZINE HIBENZATE
Common Name English
PRENOXDIAZINE COMPD WITH 2-(4-HYDROXYBENZOYL)BENZOIC ACID
MI  
Common Name English
DIPHENYLETHYL)-5-(2-PIPERIDINOETHYL)-1,2,4-OXADIAZOLE 2-(4-HYDROXYBENZOYL)BENZOATE
Common Name English
PRENOXDIAZINE HYBENZATE
Common Name English
Prenoxdiazin hydroxybenzoylbenzoate [WHO-DD]
Common Name English
PRENOXDIAZIN HYDROXYBENZOYLBENZOATE
WHO-DD  
Common Name English
LIBEXIN 2-(4-HYDROXYBENZOYL)BENZOATE
Common Name English
PRENOXDIAZINE COMPD WITH 2-(4-HYDROXYBENZOYL)BENZOIC ACID [MI]
Common Name English
Code System Code Type Description
CAS
37671-82-2
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID40191087
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY
FDA UNII
VAT8R7N21U
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY
PUBCHEM
13059698
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY
MERCK INDEX
m9124
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY Merck Index
EVMPD
SUB04031MIG
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY
SMS_ID
100000085096
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY
ECHA (EC/EINECS)
253-584-6
Created by admin on Sat Dec 16 05:31:54 GMT 2023 , Edited by admin on Sat Dec 16 05:31:54 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of PRENOXDIAZINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966